Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an exclusive global license for opevesostat (MK-5684/ODM-208) and other CYP11A1 targeting candidates, following a mutual agreement with Orion Corporation. This pivotal deal marks a significant advancement in the treatment of prostate […]
In a significant step towards finalizing the acquisition, Fusion Pharmaceuticals Inc.’s shareholders have overwhelmingly voted in favor of the proposed acquisition by AstraZeneca. During a special virtual meeting, approximately 80.83% of Fusion’s issued and outstanding shares were represented, with 99.92% of these votes endorsing the acquisition under the terms of a plan of arrangement as […]
